#China #Chengdu #WuXi Biologics #microbial manufacturing

WuXi Biologics Marks Major Milestone in Chengdu

WuXi Biologics, a prominent player in the global Contract Research, Development, and Manufacturing Organization (CRDMO) sector, recently announced a significant advancement in its Chengdu operations. The microbial manufacturing site has achieved structural completion, alongside the arrival of essential equipment. This development not only marks a substantial milestone for the company but also sets the stage for the release of Good Manufacturing Practice (GMP)-certified products by the end of 2026.

Overview of the Chengdu Facility

Located in the Wenjiang District of Chengdu, the new facility occupies approximately 95,000 square meters and is engineered specifically for the commercial production of drug substances (DS) and drug products (DP) derived from microbial sources. This strategic initiative is aimed at enhancing the company's manufacturing capabilities for various next-generation therapies, including antibody-drug conjugates (ADCs), cell therapies, bi- and multi-specific antibodies, and cancer vaccines. These advanced therapeutics often utilize recombinant proteins such as polypeptides, enzymes, antibody fragments, nanobodies, and cytokines, which can be produced at scale using microbial fermentation processes.

Microbial fermentation is gaining considerable traction in the biopharmaceutical industry due to its myriad advantages, including high yield, rapid development timelines, scalability, process consistency, and cost-effectiveness.

State-of-the-Art Manufacturing Capabilities

Once fully operational, the Chengdu site will house a 15,000-liter fermenter with the capacity to produce up to 110 DS batches annually. Furthermore, there is long-term potential for expansion to a 60,000-liter fermenter. The facility will also feature China’s first dual-chamber lyophilization production line, developed in collaboration with VISEN Pharmaceuticals, alongside a vial-filling line capable of delivering more than 10 million vials per year, significantly boosting its capabilities in commercial manufacturing specialized for complex formulations.

Moreover, the site is designed with integrated automation and digital systems that span both upstream and downstream operations, ensuring compliance with GMP standards while enhancing operational efficiency and data integrity. Sustainable practices are also embedded in the facility's design, utilizing green building practices and photovoltaic (PV) modules to improve energy and resource efficiency.

Vision for Future Growth

Dr. Chris Chen, the CEO of WuXi Biologics, expressed that the completion of the Chengdu microbial manufacturing site signifies a pivotal progression in bolstering the company’s commercial-scale microbial capabilities. The facility not only aims for efficient technology transfer but also showcases the increasing adoption of microbial technologies in emerging modalities and enhanced therapies. This aligns with WuXi's overarching vision to deliver comprehensive CRDMO services that bridge the gap from initial strain development to commercial manufacturing, catering to global pharmaceutical innovators.

With the proprietary E. coli expression system, named EffiX™, WuXi Biologics achieves remarkable recombinant protein titers of up to 15 g/L, and can provide a complete Chemistry, Manufacturing, and Controls (CMC) package from plasmid DNA to Investigational New Drug (IND) filing in just six months. The microbial platform is equipped for scale-up production, effectively transitioning from 15 liters to 15,000 liters in line with the varying demands of preclinical, clinical, and commercial needs. By the close of 2025, WuXi’s integrated microbial fermentation platform had successfully supported the development and manufacturing of 128 distinct molecules, reflecting its growth and commitment to innovation in the biopharmaceutical sector.

Commitment to Sustainability

Promoting sustainability remains a core principle for WuXi Biologics as it aims to evolve its business responsibly. The company continually drives technological innovations while offering advanced end-to-end Green CRDMO solutions designed for its global partners. By prioritizing Environmental, Social, and Governance (ESG) best practices, WuXi Biologics demonstrates a commitment to create shared value and positive social and environmental impacts, working closely with all stakeholders throughout its value chain.

For more detailed information about WuXi Biologics and their innovative practices, please visit WuXi Biologics.